ImmunityBio
IBRX
IBRX
145 hedge funds and large institutions have $89.2M invested in ImmunityBio in 2023 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 40 increasing their positions, 42 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
1.61% less ownership
Funds ownership: 12.21% → 10.6% (-1.6%)
65% less capital invested
Capital invested by funds: $256M → $89.2M (-$167M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Holders
145
Holding in Top 10
–
Calls
$1.32M
Puts
$1.27M
Top Buyers
| 1 | +$10.5M | |
| 2 | +$5.07M | |
| 3 | +$2.87M | |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.99M |
| 5 |
Millennium Management
New York
|
+$948K |
Top Sellers
| 1 | -$38.6M | |
| 2 | -$7.44M | |
| 3 | -$2.39M | |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$1.5M |
| 5 |
Goldman Sachs
New York
|
-$1.45M |